Form D · Biotechnology
OS Therapies Inc
Grasonville, MD · CIK 0001795091
Offering snapshot reported Aug 25, 2026 · SEC filing
- Reported sold
- $5M Offering amount: $10M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2026 | Initial | $5,000,000 | No comparison | 10 | SEC filing |
| Jul 16, 2026 | Initial | $1,600,000 | No comparison | 1 | SEC filing |
| Mar 6, 2026 | Initial | $2,000,000 | No comparison | 9 | SEC filing |
| Jan 20, 2026 | Initial | $3,498,650 | No comparison | 9 | SEC filing |
| Sep 10, 2025 | Initial | $3,777,808 | No comparison | 10 | SEC filing |
| Jul 16, 2025 | Initial | $4,216,794 | No comparison | 27 | SEC filing |
| Jan 22, 2025 | Initial | $7,103,000 | No comparison | 34 | SEC filing |
| Dec 14, 2023 | Initial | $700,000 | No comparison | 3 | SEC filing |
| Jan 11, 2023 | Initial | $2,000,000 | No comparison | 11 | SEC filing |
| Sep 1, 2021 | Initial | $1,000,000 | No comparison | Not reported | SEC filing |
| May 1, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 5, 2019 | Initial | $359,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $500K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-595322
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Ceros Financial Services, Inc. | 37869 |
Source: Form D, filed Aug 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher P. Acevedo | Executive |
| Joacim Borg | Director |
| John Ciccio | Director |
| Gerald Commissiong | Executive |
| Craig Eagle | Director |
| Karim Galzahr | Director |
| Colin Goddard | Director |
| Olivier Jarry | Director |
| Avril Mc Kean Dieser | Director |
| Robert G. Petit | Executive |
| Paul A. Romness | Director, Executive |
| Theodore F. Search | Director |
| Jutta Wanner | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
115 Pullman Crossing Road Suite 103
Grasonville, MD, 21638
Phone: 410-297-7793
Grasonville, MD, 21638
Phone: 410-297-7793